Literature DB >> 15102428

Intraplantar zymosan as a reliable, quantifiable model of thermal and mechanical hyperalgesia in the rat.

S T Meller1, G F Gebhart.   

Abstract

The study of the mechanisms of thermal and mechanical hyperalgesia produced in human inflammatory conditions is dependent on a reliable, consistent model. The present investigation shows that the intraplantar administration of zymosan in the rat hindpaw produces a reliable and quantifiable thermal and mechanical hyperalgesia accompanied by oedema that closely mimics the symptoms of inflammation in man. Prior to the intraplantar injection of zymosan, there was no significant difference in withdrawal latencies, mechanical withdrawal thresholds or paw thickness between the left and right hindpaws. The intraplantar injection of zymosan (0.313-6.25 mg), an extract from yeast, produced a dose- and time-dependent thermal and mechanical hyperalgesia, a robust oedema and, at the greatest doses, produced evidence of spontaneous pain. At the least dose of zymosan tested (0.313 mg), there was a slight oedema; oedema was greatest at dosages > or =2.5 mg and was always maximal by 30 min postinjection, irrespective of the dose. On the other hand, thermal and mechanical hyperalgesia showed a more complex dose- and time-dependence. Mechanical hyperalgesia did not appear until dosages > or =1.25 mg and was maximal by 5 mg. In addition, mechanical hyperalgesia showed a time-dependent progressive onset so that hyperalgesia was maximal by the 4-h testing time-point. In contrast, thermal hyperalgesia showed a biphasic nature with two apparent maximal time-points (30 min and 4 h). There was an early-phase thermal hyperalgesia (maximal by 30 min) that was dose-dependent at dosages > or =2.5 mg (not apparent at lower dosages) and a late-phase (maximal by 4 h) that was dose-dependent at dosages > or =0.0625 mg. At the greatest doses administered (5 and 6.25 mg), there was evidence of spontaneous pain from the time of injection for up to 4 h that was characterized by occasional spontaneous flicking of the hindpaw, but more usually by holding the paw in an elevated position for extended periods of time. In addition, at the greatest dose tested (6.25 mg), all rats showed evidence of licking, biting and shaking of the injected hindpaw for up to 30-45 min after injection. These data demonstrate that the intraplantar injection of zymosan is a reliable and quantifiable model of tonic pain characterized by a dose- and time-dependent thermal and mechanical hyperalgesia accompanied by a robust oedema. This model is likely to be a useful, reliable model in which to study further the central and peripheral mechanisms of hyperalgesia.

Entities:  

Year:  1997        PMID: 15102428     DOI: 10.1016/s1090-3801(97)90052-5

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  27 in total

Review 1.  Infection, Pain, and Itch.

Authors:  Isaac M Chiu
Journal:  Neurosci Bull       Date:  2017-01-31       Impact factor: 5.203

2.  The leukotriene B4 receptors BLT1 and BLT2 form an antagonistic sensitizing system in peripheral sensory neurons.

Authors:  Sebastian Zinn; Marco Sisignano; Katharina Kern; Sandra Pierre; Sorin Tunaru; Holger Jordan; Jing Suo; Elsa-Marie Treutlein; Carlo Angioni; Nerea Ferreiros; Andreas Leffler; Natasja DeBruin; Stefan Offermanns; Gerd Geisslinger; Klaus Scholich
Journal:  J Biol Chem       Date:  2017-02-27       Impact factor: 5.157

Review 3.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

4.  Heritability of nociception IV: neuropathic pain assays are genetically distinct across methods of peripheral nerve injury.

Authors:  Erin E Young; Michael Costigan; Teri A Herbert; William R Lariviere
Journal:  Pain       Date:  2013-09-24       Impact factor: 6.961

5.  TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17.

Authors:  Andrew D Cook; Ming-Chin Lee; Reem Saleh; Hsu-Wei Khiew; Anne D Christensen; Adrian Achuthan; Andrew J Fleetwood; Derek C Lacey; Julia E Smith; Irmgard Förster; John A Hamilton
Journal:  JCI Insight       Date:  2018-03-22

6.  HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain.

Authors:  Alessandra Di Lio; Dietmar Benke; Marie Besson; Jules Desmeules; Youssef Daali; Zhi-jian Wang; Rahul Edwankar; James M Cook; Hanns Ulrich Zeilhofer
Journal:  Neuropharmacology       Date:  2010-12-08       Impact factor: 5.250

7.  Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation.

Authors:  Adrian Achuthan; Andrew D Cook; Ming-Chin Lee; Reem Saleh; Hsu-Wei Khiew; Melody W N Chang; Cynthia Louis; Andrew J Fleetwood; Derek C Lacey; Anne D Christensen; Ashlee T Frye; Pui Yeng Lam; Hitoshi Kusano; Koji Nomura; Nancy Steiner; Irmgard Förster; Stephen L Nutt; Moshe Olshansky; Stephen J Turner; John A Hamilton
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

8.  Glutamate-mediated astrocyte-to-neuron signalling in the rat dorsal horn.

Authors:  Rita Bardoni; Alessia Ghirri; Micaela Zonta; Chiara Betelli; Giovanni Vitale; Valentina Ruggieri; Maurizio Sandrini; Giorgio Carmignoto
Journal:  J Physiol       Date:  2010-01-18       Impact factor: 5.182

9.  COX-2 expression and function in the hyperalgesic response to paw inflammation in mice.

Authors:  Naveen K Jain; Tomo-o Ishikawa; Igor Spigelman; Harvey R Herschman
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2008-10-01       Impact factor: 4.006

10.  cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I.

Authors:  Achim Schmidtko; Wei Gao; Peter König; Sandra Heine; Roberto Motterlini; Peter Ruth; Jens Schlossmann; Doris Koesling; Ellen Niederberger; Irmgard Tegeder; Andreas Friebe; Gerd Geisslinger
Journal:  J Neurosci       Date:  2008-08-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.